(0) items in cart / view cart / checkout  
 
 
  Aerospace and Defense
  Automotive
  Chemicals
  Consumer Packaged Goods
  Energy and Utilities
  Financial Services
  Geography
  Government and Non-Profit Organisations
  Industrial Goods and Machinery
  Ingredients
  Knowledge Center
  Leisure and Arts
  Media
  Paper and Packaging
  Pharmaceuticals and Healthcare
  Retailing
  ServiceLine
  Technology and Communications
  Textiles
  Transport and Logistics
  Wholesale
 
Home >  Commercial Insight: Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment

 
Commercial Insight: Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment


The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016

Assessment of current and future opportunities and threats in the MS market across the 7MMs

Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs

Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market
Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. Datamonitor believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.

In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxonelaunched in 1997Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.

There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idec's strategy to market two or more products and show commitment to the MS community through long-term franchise investment.
Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands

Quantify the future size of the MS market, in terms of volume and value, in each of the 7MM

Identify key lifecycle management strategies that can ensure growth in the competitive MS market


     
  Published Price
06/27/2007
   $15200.00
   Free Shipping Worldwide

 
 
VPGDataMonitor.com © Copyright 2008. all rights reserved. Web Design by Spida Design